Dementia Discovery Fund
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is the world's largest family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia and other neurodegenerative diseases. Launched in October 2015, it creates and backs biotech ventures across the full spectrum from early-stage research to growth equity.
32% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (41% of deals). Average disclosed round size is $52.9M (across 18 rounds with reported amounts).
Portfolio
17
Fund Size
$269M
Top Stage
Series A
Last 12 Mo
0
Team
Christian B. Jung
Partner
Jonathan Behr
Partner
Georgia Frost
Vice President
Lennart R. B. Spindler
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| TTherini Bio | Series A | $39M | May 2025 |
 Sudo Biosciences | Series B | $147M | Jan 2024 |
 Sudo | Series B | $147M | Jan 2024 |
 AstronautX | Series A | $61M | Oct 2023 |
| VViolet Therapeutics Inc. | Seed | $10.6M | May 2023 |
| QQualis Corporation | Series B | $88M | Mar 2023 |
| TTransine Therapeutics | Seed | $5.8M | May 2022 |
 AviadoBio | Seed | $16.5M | Dec 2021 |
 Nitrase Therapeutics | Series A | $45M | Nov 2021 |
| TTransine Therapeutics | Seed | $12.8M | Jun 2021 |
 Alchemab Therapeutics | Series A | $60M | Apr 2021 |
| AviadoBio | Series A | $80M | Jan 2021 |
| AAlchemab | Series A | $60M | Jan 2021 |
| Alchemab Therapeutics | Seed | — | Jan 2019 |
| AAlchemab | Seed | — | Jan 2019 |
| RRheostat Therapeutics | Series A | $23M | Nov 2018 |
| MMitoconix Bio | Series A | $20M | Jun 2017 |
 QurAlis | Series B | $88M | — |
 Violet | Seed | $10.6M | — |
 Harness Therapeutics | Grant | — | — |
| RRheostat Therapeutics | Seed | — | — |
| NNitrome Biosciences | Series A | $38M | — |
Top Co-Investors
Last updated: 8 September 2026